Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Adrenergic Agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Refer to a class of agents that acts upon adrenergic receptors associated with activities of Sympathetic Nerve System. The adrenergic receptors (adrenoceptors) belongs to the family of seven membrane spanning domain receptors that require G protein signaling pathway. (NCI04)
Drug delivery to the anterior and posterior segments of the eye using eye drops
InactiveUS20110104155A1Detection is simple and fastBiocideSenses disorderAdrenergic DrugsAdrenergic Agent
A method and means for delivery of drugs to the chorio-retina and the optic nerve head which comprises contacting the surface of the eye with an effective amount of drug for treatment of chorio-retina and optic nerve head and a physiologically acceptable adrenergic agent for enhancing delivery of the drug to these tissues in an ophtalmologically acceptable carrier, said adrenergic agent being selected from the group consisting of alpha adrenergic agonist agents, derivatives of the alpha adrenergic agonist agents, beta-blocking agents, derivatives of the beta-blocking agents and mixtures thereof.
Owner:RAOUF REKIK
Compositions and uses of alpha-adrenergic agents
The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.
Owner:LEVATION PHARMA LTD
Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and / or treatment of inflammatory and / or obstructive airways diseases.
Owner:CHIESI FARM SPA
Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and / or treatment of inflammatory and / or obstructive airways diseases.
Owner:CHIESI FARM SPA
Novel Therapeutic Treatments Using Centhaquin
Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR
Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha2 adrenergic receptors.
Owner:ALLERGAN INC
Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and / or treatment of an inflammatory and / or obstructive airways disease.
Owner:CHIESI FARM SPA
Methods and Compositions for Hypotensive Resuscitation
Methods of treating diseases and conditions wherein an improvement in cardiac output, organ perfusion, or tissue oxygenation are disclosed. The methods include treatments of diseases and conditions, such as hypovolemic shock, with an a2 adrenergic agent, like centhaquin and centhaquin citrate. The method utilizes an a2 adrenergic agent administered at low doses with a low volume of resuscitation fluid. Purified centhaquin and centhaquin citrate also are disclosed.
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR +1
Sustained release device and method for ocular delivery of adrenergic agents
The invention provides a device and method for treating and / or preventing raised intraocular pressure, such as that associated with glaucoma or the use of corticosteroids with adrenergic agents. The invention provides insertable sustained-release devices adapted to maintain a therapeutically effective concentration of one or more adrenergic agents for an extended period of time, and a method of use thereof.
Owner:CONTROL DELIVERY SYST
Selective subtype alpha 2 adrenergic agents and methods for use thereof
The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
Owner:ALLERGAN INC
Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and / or treatment of an inflammatory and / or obstructive airways disease.
Owner:CHIESI FARM SPA
Compositions and uses of alpha-adrenergic agents
Owner:LEVATION PHARMA LTD
Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
Owner:ALLERGAN INC
Sustained release system and method for ocular delivery of carbonic anhydrase inhibitors
Owner:普斯维达美国有限公司
Novel Therapeutic Treatments Using Centhaquin
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR
Controlled release of highly soluble agents
The invention provides a device and method for treating and / or preventing raised intraocular pressure, such as that associated with glaucoma or the use of corticosteroids with adrenergic agents. The invention provides insertable sustained-release devices adapted to maintain a therapeutically effective concentration of one or more adrenergic agents for an extended period of time, and a method of use thereof.
Owner:控释给药系统公司
Selective subtype alpha 2 adrenergic agents and methods for use thereof
Owner:ALLERGAN INC
Anti-sneeze and nose vestibule care - compositions, methods, and devices
Compositions, methods, and devices are herein disclosed for anti-sneeze and nose vestibule care for humans and other animals. An anti-sneeze composition includes an adrenergic agent, an anticholinergic agent, an antihistamine, a plasticizer for nose skin / nose muscle, and a soothing agent. A version of nose vestibule care composition includes alternative functional agents, such as anti-inflammatory agents, anti-oxidants, and antimicrobials, besides adrenergic, anticholinergic, and antihistamine agents. The alternative or additional agents are present in the invented composition for the purposes of wellness care of noses, prevention of diseases or aiding a medical treatment. The methods and devices for delivering the compositions to the nose vestibules for anti-sneeze, for wellness care, preventive care measure against diseases, and for aiding medical treatment of diseases are prescribed.
Owner:LI YONGHUA
Selective subtype alpha 2 adrenergic agents and methods for use thereof
Owner:ALLERGAN INC
Selective subtype alpha 2 adrenergic agents and methods for use thereof
The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
Owner:ALLERGAN INC
Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
Owner:CHIESI FARM SPA
Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
ActiveUS10786450B2Powder deliveryPharmaceutical non-active ingredientsAnticholinergic agentsInhalation
Owner:CHIESI FARM SPA
Selective subtype alpha 2 adrenergic agents and methods for use thereof
InactiveUS20110034517A1Clear processBiocideSenses disorderAlpha-2 adrenergic receptorSubtype selective
The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
Owner:ALLERGAN INC
Selective subtype alpha 2 adrenergic agents and methods for use thereof
Owner:ALLERGAN INC
Selective subtype alpha 2 adrenergic agents and methods for use thereof
The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and / or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders.
Owner:ALLERGAN INC
Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
The present disclosure is related to methods and compositions for treating or preventing kidney injury or failure, comprising administering an endothelin B (ETB) receptor agonist and / or an alpha 2 adrenergic agent.
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR +1
Selective subtype alpha 2 adrenergic agents and methods for use thereof
Owner:ALLERGAN INC
Drug delivery to the anterior and posterior segments of the eye using eye drops
InactiveUS20140011809A1Detection is simple and fastBiocideSenses disorderAdrenergic DrugsAdrenergic Agent
Owner:REKIK RAOUF
Selective subtype alpha 2 adrenergic agents and methods for use thereof
ActiveUS20110105526A1Clear processBiocideSenses disorderAlpha-2 adrenergic receptorSubtype selective
The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
Owner:ALLERGAN INC
Therapeutic treatments using centhaquin
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com